{"filings":[{"id":667556,"accession_number":"0001145197-26-000132","cik":1145197,"company_name":"INSULET CORP","ticker":"PODD","form_type":"8-K","filed_at":"2026-05-26T20:06:27+00:00","items":["7.01","9.01"],"status":"ready","headline":"Insulet voluntary correction for ~7M Omnipod Pods due to cannula tear, up to $50M cost","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["~7M Pods affected (60% consumed/expired); 24 serious adverse events (hospitalization/DKA), no deaths.","Up to $50M cost in 2026 excluded from adjusted results; no change to 2026 guidance.","Separate from March 2026 correction; cause identified and corrective actions implemented.","No expected disruption to shipments, product availability, or new customer starts."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":9916622620.83145,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":581861,"accession_number":"0001145197-26-000121","cik":1145197,"company_name":"INSULET CORP","ticker":"PODD","form_type":"8-K","filed_at":"2026-05-21T20:03:22+00:00","items":["5.03","5.07","9.01"],"status":"ready","headline":"Insulet adopts exclusive forum bylaws; shareholders elect directors and approve Say-on-Pay","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Amended bylaws designate Delaware Chancery Court as exclusive forum for derivative and fiduciary duty claims.","Federal district courts designated as exclusive forum for Securities Act claims.","Three Class I directors elected with 89-93% of votes cast; quorum was 89.19%.","Say-on-Pay advisory vote passed with 53.4M for, 4.7M against, 0.7M abstentions.","PricewaterhouseCoopers ratified as auditor for FY 2026 with 61.7M votes for."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.35,"calibrated_materiality_score":0.35,"market_cap_usd":9916622620.83145,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":91565,"accession_number":"0001145197-26-000100","cik":1145197,"company_name":"INSULET CORP","ticker":"PODD","form_type":"8-K","filed_at":"2026-05-06T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Insulet Q1 revenue $761.7M (+33.9%), beats guidance; raises FY revenue outlook","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q1 revenue $761.7M, up 33.9% YoY (30.1% constant currency), exceeding guidance range of 25-27% constant currency.","GAAP diluted EPS $1.30 vs $0.50 prior year; adjusted EPS $1.42 vs $1.02.","U.S. Omnipod revenue $515.6M (+28.3%); International $242.9M (+59.4%, +45.2% constant currency).","Adjusted operating income margin 17.5% (up 110 bps YoY); net income $91.1M vs $35.4M.","Launched Omnipod 5 algorithm update with new 100 mg/dL target; limited market release with FreeStyle Libre 3 Plus."],"consensus_eps_estimate":null,"consensus_eps_actual":1.3,"consensus_revenue_estimate":null,"consensus_revenue_actual":761700000.0,"consensus_period":"2026-Q1","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":9916622620.83145,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":91564,"accession_number":"0001145197-26-000095","cik":1145197,"company_name":"INSULET CORP","ticker":"PODD","form_type":"8-K","filed_at":"2026-04-29T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Insulet Corporation updates on voluntary Medical Device Correction with FDA reporting 476 serious injuries","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["On March 12, 2026, Insulet issued a press release regarding a voluntary Medical Device Correction with 18 Serious Adverse Events reported.","On April 10, 2026, Insulet added 13 expired lots to the correction, stating no impact on previously estimated financial impact.","As of April 17, 2026, FDA reported 476 serious injuries and no deaths associated with the device issue; Insulet clarified these are Medical Device Reports, not confirmed adverse events.","The updated communication on April 10 noted 29 confirmed Serious Adverse Events, up from the initial 18."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":9916622620.83145,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":101754,"accession_number":"0001145197-26-000081","cik":1145197,"company_name":"INSULET CORP","ticker":"PODD","form_type":"8-K","filed_at":"2026-03-12T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Insulet voluntarily corrects Omnipod 5 pods; 18 serious adverse events, up to $40M cost","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Voluntary medical device correction for specific lots of Omnipod 5 Pods due to small tear in internal tubing causing under-delivery of insulin.","Insulet received 18 reports of serious adverse events including hospitalization and DKA; no deaths reported.","Affected pods represent approximately 1.5% of annual Omnipod 5 production; other products unaffected.","Insulet expects up to $40 million in correction costs in 2026, excluded from adjusted results; 2026 guidance unchanged.","Insulet implemented manufacturing process updates and notified FDA; customers can check lot numbers and get free replacements."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":9916622620.83145,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":101753,"accession_number":"0001145197-26-000078","cik":1145197,"company_name":"INSULET CORP","ticker":"PODD","form_type":"8-K","filed_at":"2026-03-04T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Insulet finalizes severance with ex-CFO Chadwick; no new material terms","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Severance agreement signed Feb 27, 2026 with former CFO Ana M. Chadwick.","Terms unchanged from prior disclosures (8-K Sept 2025, Executive Severance Plan April 2025).","Includes standard release, non-disparagement, and compliance with existing confidentiality/non-compete agreement."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":9916622620.83145,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":101750,"accession_number":"0001145197-26-000033","cik":1145197,"company_name":"INSULET CORP","ticker":"PODD","form_type":"8-K/A","filed_at":"2026-02-24T23:59:59+00:00","items":["4.01","9.01"],"status":"ready","headline":"Insulet finalizes auditor change: Grant Thornton out, PwC in for FY2026","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Grant Thornton completed its audit for FY2025; dismissal effective Feb 18, 2026.","PwC selected as independent auditor for fiscal year ending Dec 31, 2026.","No disagreements or reportable events with Grant Thornton during 2024, 2025, or interim 2026.","No prior consultations with PwC on accounting or auditing matters.","GT's audit reports for 2024 and 2025 had no adverse or qualified opinions."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.25,"calibrated_materiality_score":0.25,"market_cap_usd":9916622620.83145,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":101752,"accession_number":"0001145197-26-000026","cik":1145197,"company_name":"INSULET CORP","ticker":"PODD","form_type":"8-K","filed_at":"2026-02-18T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"Insulet Q4 revenue $783.8M (+31%), full year $2.7B (+31%); Board ups buyback by $350M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q4 revenue $783.8M (+31.2% YoY) exceeded constant-currency guidance of 25-28%.","Q4 diluted EPS $1.44 GAAP; adjusted EPS $1.55 (+34.8% YoY).","Full year 2025 revenue $2.7B (+30.7%); gross margin 71.6% (+180 bps), operating margin 17.5% (+260 bps).","Operating cash flow $569.3M; free cash flow $377.7M, both up vs prior year.","Board increased share repurchase authorization by $350M (total $475M); plans ~$300M repurchases in Q1 2026."],"consensus_eps_estimate":null,"consensus_eps_actual":3.48,"consensus_revenue_estimate":null,"consensus_revenue_actual":2708100000.0,"consensus_period":"2025-FY","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":9916622620.83145,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":101751,"accession_number":"0001145197-26-000007","cik":1145197,"company_name":"INSULET CORP","ticker":"PODD","form_type":"8-K","filed_at":"2026-02-03T23:59:59+00:00","items":["1.01","9.01"],"status":"ready","headline":"Insulet extends supply agreement with NXP USA through 2026, amends terms","summary_kind":"llm","event_type":"other_material","confidence":"low","bullets":["Extended purchase agreement with NXP USA for period Jan 1-Dec 31, 2026.","Amended pricing and order flexibility terms; confidential details omitted.","Replaced prior flexibility table with new zone-based schedule for quantity changes.","All other terms of the original 2017 agreement remain in effect.","NXP is a key supplier for Insulet's products; no financial impact disclosed."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":9916622620.83145,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":118067,"accession_number":"0001628280-25-058252","cik":1145197,"company_name":"INSULET CORP","ticker":"PODD","form_type":"8-K","filed_at":"2025-12-19T23:59:59+00:00","items":["4.01","9.01"],"status":"ready","headline":"Insulet dismisses Grant Thornton, appoints PwC as auditor for FY 2026","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Audit Committee approved PwC as independent auditor for FY 2026, subject to client acceptance; Grant Thornton dismissed.","Grant Thornton's reports for FY 2024 and 2023 had no adverse opinion and were not qualified or modified.","No disagreements or reportable events occurred between Insulet and Grant Thornton during 2024, 2023, and interim through Dec 15, 2025.","Previously disclosed material weakness (ITGC outside North America) has been remediated as of FY 2024.","Grant Thornton will complete the FY 2025 audit; PwC begins with FY 2026."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":9916622620.83145,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":118066,"accession_number":"0001145197-25-000077","cik":1145197,"company_name":"INSULET CORP","ticker":"PODD","form_type":"8-K","filed_at":"2025-12-17T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"Insulet amends annual incentive plan effective Jan 1, 2026; expands retirement and clawback provisions","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Plan clarifies 'for Cause' definition and expands clawback/recoupment language.","Prorated award eligibility for Retirement if age+service ≥ 60, age ≥ 50, and ≥ 4 years service.","Termination without Cause after March 31 now eligible for prorated award (previously excluded).","Maximum award increased to 2.5x Target Award for participants (effective Jan 1, 2025).","Other changes: notice requirement for Retirement (120 days), expanded award eligibility for certain terminations."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.2,"market_cap_usd":9916622620.83145,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":118065,"accession_number":"0001145197-25-000067","cik":1145197,"company_name":"INSULET CORP","ticker":"PODD","form_type":"8-K","filed_at":"2025-11-06T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Insulet Q3 EPS $1.24 beats; revenue up 30% YoY; raises FY guidance","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue $706.3M (+29.9% YoY), exceeding 22-25% constant-currency guidance range.","GAAP diluted EPS $1.24 vs $1.08 YoY; adjusted EPS $1.24 vs $0.90 YoY.","Gross margin 72.2% (+290 bps); operating margin 16.7% (+50 bps).","Raised full-year revenue growth and adjusted operating margin guidance.","Redeemed remaining $380M convertible notes in the quarter."],"consensus_eps_estimate":null,"consensus_eps_actual":2.05,"consensus_revenue_estimate":null,"consensus_revenue_actual":1924300000.0,"consensus_period":"2025-Q3","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":9916622620.83145,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":118064,"accession_number":"0001145197-25-000058","cik":1145197,"company_name":"INSULET CORP","ticker":"PODD","form_type":"8-K","filed_at":"2025-10-23T23:59:59+00:00","items":["5.02","7.01","9.01"],"status":"ready","headline":"Insulet appoints former JPMorgan investment banking chair Robbie Huffines to board","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Robbie Huffines appointed as independent Class II director, effective October 31, 2025.","He will serve on the Audit Committee; will stand for election at 2027 Annual Meeting.","Huffines was Global Chair of Investment Banking at JPMorgan Chase (2020-2024) and co-head of global healthcare investment banking.","No arrangements or related-party transactions were disclosed in connection with his appointment."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.35,"calibrated_materiality_score":0.35,"market_cap_usd":9916622620.83145,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":134515,"accession_number":"0001193125-25-204276","cik":1145197,"company_name":"INSULET CORP","ticker":"PODD","form_type":"8-K","filed_at":"2025-09-16T23:59:59+00:00","items":["5.02","8.01","9.01"],"status":"ready","headline":"Insulet appoints Flavia Pease as CFO effective Sept 30; expects to exceed Q3 revenue guidance","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Ana Chadwick departs as CFO; Flavia Pease, former Charles River Labs CFO, assumes role on Sept 30, 2025.","Pease receives $1.325M cash sign-on, $715K base salary, 70% bonus target, and $3.76M in equity awards.","Chadwick to receive severance per company plan plus one-time cash payment equal to value of equity vesting May 1, 2026.","Insulet expects to exceed its previously issued Q3 2025 total revenue growth guidance, driven by strong new customer starts."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":9916622620.83145,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":134514,"accession_number":"0001145197-25-000037","cik":1145197,"company_name":"INSULET CORP","ticker":"PODD","form_type":"8-K","filed_at":"2025-08-07T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Insulet Q2 revenue $649M (+32.9%), beats guidance; raises full-year outlook","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue $649.1M, up 32.9% YoY (31.3% constant currency), above 26% constant-currency guidance.","U.S. Omnipod revenue $453.2M (+28.7%); International $185.8M (+45.0%, or 38.8% constant currency).","Adjusted diluted EPS $1.17 vs $0.55; adjusted operating income $115.8M (17.8% of revenue).","Full-year revenue and adjusted operating margin guidance raised (no specific figures in excerpt).","Gross margin 69.7% (up 190 bps); adjusted EBITDA $157.5M (24.3% of revenue)."],"consensus_eps_estimate":null,"consensus_eps_actual":0.82,"consensus_revenue_estimate":null,"consensus_revenue_actual":1218100000.0,"consensus_period":"2025-Q2","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":9916622620.83145,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":151358,"accession_number":"0001193125-25-137882","cik":1145197,"company_name":"INSULET CORP","ticker":"PODD","form_type":"8-K","filed_at":"2025-06-09T23:59:59+00:00","items":["1.01","1.02","2.03","8.01","9.01"],"status":"ready","headline":"Insulet refinances $481.25M term loan at lower rate, redeems 0.375% convertible notes due 2026","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["Refinanced $481.25M term loans with new term loans at 0.50% lower interest rate margin (2.00% for Term SOFR loans).","Reduced interest rate margin on revolving credit facility from 2.00%-2.50% to 1.50%-2.00% for Term SOFR loans.","Notice to redeem all outstanding 0.375% Convertible Senior Notes due 2026 on Aug 20, 2025 at 100% principal plus accrued interest.","Terminated capped call transactions associated with the notes; expects hedge unwind activity including stock sales."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":9916622620.83145,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":151357,"accession_number":"0001145197-25-000030","cik":1145197,"company_name":"INSULET CORP","ticker":"PODD","form_type":"8-K","filed_at":"2025-05-28T23:59:59+00:00","items":["5.02","5.07","9.01"],"status":"ready","headline":"Insulet shareholders approve 2025 equity plan adding 7.4M shares; all director nominees elected","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["2025 Stock Option and Incentive Plan approved (59.9M for, 3.3M against), authorizing 7.4M new shares.","Class III directors Hopfield, McEvoy, Weatherman elected with >94% of votes cast.","Say-on-pay advisory vote received ~93% support (58.8M for, 4.3M against).","Ratification of Grant Thornton as auditor for FY2025 approved with 99.4% of votes cast.","Compensation Committee approved revised equity award forms for use under the new plan."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":9916622620.83145,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":151356,"accession_number":"0001145197-25-000021","cik":1145197,"company_name":"INSULET CORP","ticker":"PODD","form_type":"8-K","filed_at":"2025-05-08T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Insulet Q1 revenue up 29% YoY to $569M, raises guidance; new CEO","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue $569M (+28.8% YoY) exceeds high end of guidance; Omnipod revenue $554.1M (+28%).","Gross margin 71.9% (+240 bps); adjusted operating margin 16.4% (+350 bps).","Adjusted EPS $1.02; GAAP EPS $0.50; adjusted EBITDA $133.9M (23.5% of revenue).","Raised full-year revenue and gross margin guidance.","New CEO Ashley McEvoy; Omnipod 5 launched in Australia, Belgium, Canada, Switzerland."],"consensus_eps_estimate":null,"consensus_eps_actual":0.5,"consensus_revenue_estimate":null,"consensus_revenue_actual":569000000.0,"consensus_period":"2025-Q1","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":9916622620.83145,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":151355,"accession_number":"0001193125-25-100522","cik":1145197,"company_name":"INSULET CORP","ticker":"PODD","form_type":"8-K","filed_at":"2025-04-28T23:59:59+00:00","items":["5.02","7.01","9.01"],"status":"ready","headline":"Insulet appoints Ashley McEvoy CEO, expects Q1 revenue above guidance, raising FY outlook","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Ashley McEvoy appointed President and CEO effective April 28; succeeds Jim Hollingshead, who resigned from Board.","McEvoy was EVP and Worldwide Chairman of J&J MedTech ($30B+ revenue); also served on P&G Board.","Hollingshead terminated without cause; severance includes 2x salary ($2.3M), 2x bonus, vested 7,233 unvested RSUs.","Insulet expects to exceed Q1 revenue guidance and will raise full-year 2025 guidance; full results on May 8.","Investor Day postponed from June 5; new date to be announced."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":9916622620.83145,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":151354,"accession_number":"0001145197-25-000016","cik":1145197,"company_name":"INSULET CORP","ticker":"PODD","form_type":"8-K/A","filed_at":"2025-04-09T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"Insult Corp CTO Mark Field departs March 14; signs consulting deal through Aug 31, 2025","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Mark Field departed as SVP & CTO effective March 14, 2025.","Consulting fee of $450/hour for providing guidance to CEO through August 31, 2025.","Unvested equity continues to vest during consulting period; option exercise deadline Nov 28, 2025.","Consulting Agreement signed April 7, 2025, effective retroactively to March 14, 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":9916622620.83145,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":170252,"accession_number":"0001193125-25-059783","cik":1145197,"company_name":"INSULET CORP","ticker":"PODD","form_type":"8-K","filed_at":"2025-03-21T23:59:59+00:00","items":["1.01","2.03","7.01","9.01"],"status":"ready","headline":"Insulet issues $450M 6.50% senior notes due 2033, repurchases $419M of 0.375% convertible notes due 2026","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["Issued $450M aggregate principal of 6.50% Senior Notes due 2033; net proceeds ~$444M.","Extended $500M revolving credit facility to March 20, 2030; undrawn at closing.","Repurchased $419M aggregate principal of 0.375% Convertible Senior Notes due 2026.","First close of ~$161.4M on March 24; second close of ~$382.9M expected April 14, 2025.","Following repurchase, ~$381M of convertible notes remain outstanding; capped call unwind agreements signed."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":9916622620.83145,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":170251,"accession_number":"0001193125-25-056736","cik":1145197,"company_name":"INSULET CORP","ticker":"PODD","form_type":"8-K","filed_at":"2025-03-18T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Insulet prices $450M senior notes at 6.50% due 2033 to refinance convertible notes","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["$450M aggregate principal of senior unsecured notes due 2033, priced at 6.50% annual interest.","Net proceeds estimated at ~$444.4M; closing expected March 20, 2025.","Proceeds, with cash on hand, to redeem/repurchase outstanding 0.375% Convertible Senior Notes due 2026.","Part of refinancing to also pay fees and for general corporate purposes."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":9916622620.83145,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":170250,"accession_number":"0001193125-25-056162","cik":1145197,"company_name":"INSULET CORP","ticker":"PODD","form_type":"8-K","filed_at":"2025-03-18T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Insulet proposes $450M notes offering to refinance 2026 convertibles; seeks $200M revolver increase","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["Proposed $450M senior unsecured notes due 2033 in private placement to QIBs and non-US persons.","Proceeds to redeem or repurchase existing 0.375% Convertible Senior Notes due 2026, plus fees and general corporate purposes.","Credit agreement amendment sought: extend revolver maturity from 2028 to 2030 and increase commitments up to $500M.","Both transactions subject to market conditions; consummation of each not conditioned on the other.","Notes not registered under Securities Act; offering only via private placement memorandum."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":9916622620.83145,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":170249,"accession_number":"0001145197-25-000014","cik":1145197,"company_name":"INSULET CORP","ticker":"PODD","form_type":"8-K","filed_at":"2025-03-17T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Insult CTO Mark Field departs effective March 14; Amit Guliani named acting CTO","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Mark Field left as SVP & CTO effective March 14, 2025 to pursue other opportunities.","Amit Guliani, Group VP Software Engineering, appointed acting CTO effective immediately.","Field eligible for standard severance under Amended Executive Severance Plan; consulting agreement planned."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.45,"calibrated_materiality_score":0.45,"market_cap_usd":9916622620.83145,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":170248,"accession_number":"0001145197-25-000011","cik":1145197,"company_name":"INSULET CORP","ticker":"PODD","form_type":"8-K","filed_at":"2025-03-10T23:59:59+00:00","items":["1.01","9.01"],"status":"ready","headline":"Insulet extends NXP chip supply pact through 2025; OP5 pump terms included","summary_kind":"llm","event_type":"other_material","confidence":"low","bullets":["2025 Addendum extends purchase agreement to Dec 31, 2025 with amended pricing and volume.","Q1 2025 purchases governed by prior 2024 Addendum; PO's already placed for Q1 and Q2.","Addendum covers Insulet's OP5 pump Limited Market Release, allowing modifications.","Specific purchase quantities, pricing, and warranty details are heavily redacted in SEC filing.","Mutual monthly demand reviews and rolling forecasts added for supply chain planning."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":9916622620.83145,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":170247,"accession_number":"0001145197-25-000008","cik":1145197,"company_name":"INSULET CORP","ticker":"PODD","form_type":"8-K","filed_at":"2025-02-21T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"Insulet approves revised equity agreement forms for fiscal 2025","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Talent and Compensation Committee approved revised forms of stock option, RSU, and PSU agreements on Feb 17, 2025.","Revisions augment compensation recoupment language and update international tax/securities compliance provisions.","Changes also include additional clarifying language across all three equity agreement forms.","No departures or appointments of officers; the filing covers only compensatory arrangement updates."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.15,"calibrated_materiality_score":0.15,"market_cap_usd":9916622620.83145,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":170246,"accession_number":"0001145197-25-000006","cik":1145197,"company_name":"INSULET CORP","ticker":"PODD","form_type":"8-K","filed_at":"2025-02-20T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Insulet FY2024 revenue $2.1B (+22%), beats guidance; GAAP EPS $5.78, adjusted $3.24","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["FY2024 revenue $2.1B (+22.1% YoY), exceeds constant currency guidance of 20-21%.","GAAP net income $418.3M ($5.78/diluted) vs $206.3M prior year; includes $190.8M tax benefit.","Adjusted net income $230.4M ($3.24/diluted) vs $192.2M ($2.75) prior year.","Gross margin 69.8% (+150 bps); operating income $308.9M (14.9% of revenue).","Operating cash flow $430.3M, free cash flow $305.4M; both significantly improved."],"consensus_eps_estimate":null,"consensus_eps_actual":5.78,"consensus_revenue_estimate":null,"consensus_revenue_actual":2071600000.0,"consensus_period":"2024-FY","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":9916622620.83145,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":187260,"accession_number":"0001145197-24-000048","cik":1145197,"company_name":"INSULET CORP","ticker":"PODD","form_type":"8-K","filed_at":"2024-12-04T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Insulet awarded $452M jury verdict against EOFlow for trade secret misappropriation","summary_kind":"llm","event_type":"litigation","confidence":"high","bullets":["Jury awarded $170M compensatory and $282M exemplary damages, total $452M, for willful and malicious misappropriation.","EOFlow's ability to pay the award is uncertain; Insulet also plans to seek injunctive relief.","Verdict follows four-week trial in U.S. District Court for District of Massachusetts.","Insulet CEO states company will zealously protect trade secrets beyond patent enforcement."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":9916622620.83145,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":187259,"accession_number":"0001145197-24-000043","cik":1145197,"company_name":"INSULET CORP","ticker":"PODD","form_type":"8-K","filed_at":"2024-11-07T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Insulet Q3 revenue +26% to $543.9M; beats guidance; raises FY outlook; Omnipod 5 cleared for type 2 diabetes","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue $543.9M (+25.7% YoY); Omnipod $533.6M (+26.4%); U.S. +23.4%, International +36.1%.","GAAP net income $77.5M ($1.08 EPS) vs $51.9M ($0.74); adjusted net income $64.2M ($0.90 EPS).","Gross margin 69.3% (+150bps); operating income $88.1M (16.2% of revenue); adjusted EBITDA $126.1M (23.2%).","Received FDA clearance for Omnipod 5 for type 2 diabetes; first AID system for both T1 and T2.","Raised full-year revenue and margin guidance; Q3 revenue exceeded high end of 21% constant currency guidance."],"consensus_eps_estimate":null,"consensus_eps_actual":4.4,"consensus_revenue_estimate":null,"consensus_revenue_actual":1474100000.0,"consensus_period":"2024-Q3","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":9916622620.83145,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":203773,"accession_number":"0001145197-24-000037","cik":1145197,"company_name":"INSULET CORP","ticker":"PODD","form_type":"8-K","filed_at":"2024-08-08T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Insulet Q2 revenue up 23% to $488.5M, beats guidance; raises FY2024 outlook","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue $488.5M (+23.2% YoY), exceeds high end of guidance of 18% constant currency growth.","Omnipod revenue $480.4M (+26.3%); U.S. $352.3M (+27.3%), International $128.1M (+23.5%).","GAAP net income $188.6M ($2.59 EPS) includes $151.7M valuation release; adjusted net income $38.3M ($0.55 EPS).","Gross margin 67.7% (up 90bps) despite $13.5M inventory charge; operating margin 11.2% vs 7.8% prior year.","Raises full-year 2024 revenue, gross margin, and operating margin guidance."],"consensus_eps_estimate":null,"consensus_eps_actual":3.32,"consensus_revenue_estimate":null,"consensus_revenue_actual":930200000.0,"consensus_period":"2024-Q2","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":9916622620.83145,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":203772,"accession_number":"0001193125-24-193356","cik":1145197,"company_name":"INSULET CORP","ticker":"PODD","form_type":"8-K","filed_at":"2024-08-05T23:59:59+00:00","items":["1.01","2.03","9.01"],"status":"ready","headline":"Insulet refinances $485M term loans, extends maturity to 2031, cuts interest margin by 0.50%","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["$485M existing term loans replaced with new term loans maturing Aug 2, 2031 (extended from May 2028).","Interest rate margin reduced to 1.50% (base) / 2.50% (SOFR), 0.50% lower than prior.","Revolving facility margin cut from 2.50%-3.00% to 2.00%-2.50% for SOFR loans; maturity unchanged.","New loans issued at 99.75% of par; proceeds used to repay prior loans and accrued interest.","No net new debt; $485M refinancing extends maturity by ~3.3 years and reduces interest cost."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":9916622620.83145,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":203771,"accession_number":"0001145197-24-000031","cik":1145197,"company_name":"INSULET CORP","ticker":"PODD","form_type":"8-K","filed_at":"2024-07-26T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Insulet Q2 preliminary revenue $488M (+23% YoY), raises FY Omnipod guidance to 18-21%","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q2 revenue $488M, up 23% YoY, exceeding guidance of 15-18% constant currency growth.","Total Omnipod revenue $480M (+26%): US $352M (+27%), International $128M (+23%, +24% CC).","Drug Delivery revenue $8M.","Raises FY 2024 total Omnipod revenue growth outlook to 18-21% from prior 15-19%.","Full Q2 results and call scheduled for August 8, 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":3.32,"consensus_revenue_estimate":null,"consensus_revenue_actual":930200000.0,"consensus_period":"2024-Q2","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":9916622620.83145,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":220345,"accession_number":"0001145197-24-000026","cik":1145197,"company_name":"INSULET CORP","ticker":"PODD","form_type":"8-K","filed_at":"2024-05-28T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Insulet shareholders elect three Class II directors, approve say-on-pay, ratify auditor at 2024 annual meeting","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["63,779,026 shares (91.08% quorum) voted at May 22, 2024 meeting.","Wayne A.I. Frederick, Flavia H. Pease, and Timothy J. Scannell elected as Class II directors for three-year terms.","Say-on-pay advisory vote passed with 59,316,205 for, 2,320,081 against, 17,634 abstentions.","Ratification of Grant Thornton LLP as independent auditor for FY2024 approved (63,343,082 for, 420,334 against)."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":9916622620.83145,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":220344,"accession_number":"0001145197-24-000024","cik":1145197,"company_name":"INSULET CORP","ticker":"PODD","form_type":"8-K","filed_at":"2024-05-20T23:59:59+00:00","items":["1.01","9.01"],"status":"ready","headline":"Insulet amends supply pact with NXP, extending term and clarifying Covid force majeure","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Addendum to 2017 Purchase Agreement with NXP USA effective January 1, 2024.","Extends the purchase period and includes a non-cancellable, non-refundable purchase order (redacted).","Clarifies that Covid-19 factory closures qualify as force majeure under the original agreement.","Amends pricing and other terms; specific figures are redacted as confidential."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.35,"calibrated_materiality_score":0.35,"market_cap_usd":9916622620.83145,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":220343,"accession_number":"0001145197-24-000021","cik":1145197,"company_name":"INSULET CORP","ticker":"PODD","form_type":"8-K","filed_at":"2024-05-09T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Insulet Q1 revenue $441.7M (+23% YoY); raises full-year guidance","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q1 revenue $441.7M, +23.3% YoY, above guidance of 17-20% constant currency; Omnipod revenue $433.0M.","Net income $51.5M ($0.73 diluted EPS) vs $23.8M ($0.34) prior year; operating margin 12.9% (up 520 bps).","Gross margin 69.5% (up 230 bps); adjusted EBITDA $89.2M (20.2% of revenue) up from 13.6%.","Raised full-year guidance; launched Omnipod 5 with Dexcom G7 in US and with Abbott/Sensor of Choice in Europe."],"consensus_eps_estimate":null,"consensus_eps_actual":0.73,"consensus_revenue_estimate":null,"consensus_revenue_actual":441700000.0,"consensus_period":"2024-Q1","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":9916622620.83145,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":240001,"accession_number":"0001145197-24-000017","cik":1145197,"company_name":"INSULET CORP","ticker":"PODD","form_type":"8-K","filed_at":"2024-03-20T23:59:59+00:00","items":["5.02","7.01","9.01"],"status":"ready","headline":"Insulet appoints Ana Maria Chadwick as CFO effective April 22, 2024","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Chadwick, previously CFO of Pitney Bowes, brings 30 years of finance experience.","Base salary $630,000, target cash bonus 70% of base, annual equity target $2.5M.","Sign-on equity award of $1M in RSUs (3-yr vest) and $125,000 cash signing bonus (clawback).","Interim CFO Lauren Budden steps down; remains Group VP, Chief Accounting Officer.","Chadwick serves on Dollar General board, chairs Audit Committee."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":9916622620.83145,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null}],"next_cursor":null}